Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04364048
Title Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rachel Sanborn
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Rush University Medical Center Chicago Illinois 60612 United States Details
Cancer Center of Kansas Wichita Kansas 67214 United States Details
HealthPartners Institute Minneapolis Minnesota 55440 United States Details
Summit Medical Group, P. A. Berkeley Heights New Jersey 07922 United States Details
Providence Portland Medical Center Portland Oregon 97213 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field